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Bcl-2, an inhibitor of apoptosis, is expressed in LPS-induced meta-
plastic goblet cells of rat airways. The present study investigated
expression of Bcl-2 in airway mucous cells of persons with cystic
fibrosis and tested in rats and mice whether its expression is respon-
sible for sustaining metaplastic mucous cells. A significantly higher
percentage of mucous cells expressed Bcl-2 in humans with cystic
fibrosis compared with control subjects with no disease or subjects
with other diseases. In LPS-instilled F344/N rats, the percentage of
Bcl-2–positive mucous cells was decreased to background levels
before the resolution of goblet cell metaplasia. Furthermore, intra-
peritoneal injection of rats with antisense oligonucleotides signifi-
cantly reduced Bcl-2 expression and goblet cell metaplasia in nasal
and pulmonary airway epithelia in rats. In contrast, sustained ex-
pression of Bcl-2 in transgenic mice by a metallothionein promoter
caused increased LPS-induced goblet cell metaplasia over 8 days
compared with wild-type mice. These studies demonstrate that
Bcl-2 expression sustains goblet cell metaplasia in various species,
that epithelial cell numbers are directly linked to the regulation of
the numbers of goblet cells, and that downregulating Bcl-2 expres-
sion reduces goblet cell metaplasia.
Keywords: apoptosis; antisense oligonucleotides; cystic fibrosis; inflam-
mation; LPS
One of the main reasons for the morbidity of patients with
chronic pulmonary diseases, such as cystic fibrosis (CF) and
asthma, is increased mucous secretions causing airway obstruc-
tion. Reduction of mucous secretions in CF is of great interest,
because intervention strategies by gene therapy approaches to
replace the CFTR gene or by reducing inflammation have largely
been unsuccessful.
Inflammatory responses recruit nonciliated columnar epithe-
lial cells into the cell cycle in large numbers (1) and thereby
increase the number of cells per millimeter of basal lamina (BL)
(2). This increase is accompanied by the appearance of mucus-
producing cells in areas normally devoid of these cells and is called
goblet cell metaplasia (GCM) (3). GCM allows the epithelium to
produce larger amounts of mucus, because both preexisting and
proliferating cells synthesize mucus (2). The generation of meta-
plastic mucous cells and the mechanisms by which inflammatory
mediators induce the synthesis of mucus and the differentiation
of surface epithelial cells into mucus-producing cells have been
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extensively studied. In contrast, mediators involved in reducing
the numbers of metaplastic mucous cells after inflammatory re-
sponses subside are not well understood.
In an attempt to understand mechanisms that reduce numbers
of metaplastic mucous cells during the resolution of inflamma-
tory responses, we discovered that metaplastic mucous cells ex-
press regulators of apoptosis from the Bcl-2 family of proteins
(4–6). Exposure of rats to LPS or allergen causes airway epithe-
lial cells to proliferate, and nonproliferating and proliferating
cells differentiate into mucous cells to establish GCM (2). Ap-
proximately 20 to 30% of the developing metaplastic mucous
cells express Bcl-2 (5). Furthermore, exposure of rats to ozone
induces GCM in nasal epithelia and Bcl-2 is expressed in epithe-
lia where GCM occurs (4).
The Bcl-2 family of cytoplasmic proteins can register diverse
forms of intracellular damage, gauge whether other cells have
provided a positive or negative death stimulus, and determine
the progression or inhibition of the suicide program (7). Bcl-2, an
inhibitor of apoptosis, is a member of a large group of regulatory
proteins that prevent or induce apoptosis. The activation of pro-
apoptotic signals leads to inactivation of Bcl-2 by Bcl-2 homology
region-3 domain-only family members and triggers Bax or Bak
to permeabilize mitochondria to release cytochrome c, which ini-
tiates the activation of caspases and DNases responsible for the
appearance of the apoptotic morphology (8–10). This morphol-
ogy includes DNA fragmentation, chromatin condensation, mem-
brane blebbing, cell shrinkage, and disassembly of the cell (10).
The present study tested the hypothesis that disruption of
mechanisms to resolve GCM could account for sustained GCM
in CF where mucous hypersecretion reduces airflow. Our find-
ings suggest that Bcl-2 plays a central role in the resolution of
GCM and may be a useful target for reducing mucus-secreting
cells in chronic diseases. Some results from these studies have
been previously reported in the form of an abstract (11).
METHODS
See the online supplement for additional details regarding laboratory
animals, in situ hybridization, microdissection of airway epithelia, poly-
merase chain reaction, and Western blot analyses.
Tissues from Human Subjects
Paraffin-embedded lung tissues with small airways were obtained under
the auspices of the University of North Carolina and the Lovelace
Respiratory Research Institute institutional review boards’ approved
protocols. Tissue sections (5-m thick) originated from 14 subjects
without lung diseases, 8 subjects with CF, and 8 subjects with diseases
such as interstitial pulmonary fibrosis, pulmonary hypertension, and
1-antitrypsin (Table 1). All histology sections represent sections of
airways and lungs excised during transplantation for end-stage lung
disease or excess portions of donors.
Laboratory Animals
Male F344/N rats (8–10 weeks old) were purchased from Frederick Cancer
Research, Frederick, MD. Bcl-2 transgenic mice on a C57Bl/6 background
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TABLE 1. DEMOGRAPHICS OF AIRWAY TISSUE DONORS
Normal (n  14) CF (n  8 ) Other (n  8 )
Mean age, yr 43 27 46
Sex 9 M, 5 F 7 M, 1 F 5 M, 3 F
Diagnosis 5 M, 1 F DF/DF 2 M IPF
1 M DF/G551D 1 M, 1F PHTN
1 F DF/621  1G  T 1 M 1-AT
1 M COPD, 2 F non-CF bronchiectasis
Definition of abbreviations: 1-AT  1-antitrypsin; CF  cystic fibrosis; COPD  chronic pulmonary obstructive disease; DF 
deletion of phenylalanine; F  female; G  T  transversion mutations; IPF  interstitial pulmonary fibrosis; M  male; PHTN 
pulmonary hypertension.
with the Bcl-2 transgene under the control of the mouse metallothionein
promoter (provided by Dr. Nelson Fausto, University of Washington,
Seattle, WA) were bred at the Lovelace Respiratory Research Institute.
Instillation for rats and mice was as described (12, 13). All experiments
were approved by the Institutional Animal Care and Use Committee
and were performed at the Lovelace Respiratory Research Institute, a
facility approved by the Association for the Assessment and Accredita-
tion for Laboratory Animal Care International.
Rat Nasal Explant Cultures and Treatment
with Antisense Oligonucleotides
Nasal explants were treated with 100 g/ml endotoxin in medium
(n  4/group) for 24 hours and maintained in culture in endotoxin-
free medium for 2 additional days. They were then fixed in zinc formalin
and processed for histologic analyses as described (14). They were
treated with 30 M antisense oligonucleotides (ASODNs) in 40 l
culture medium and 3 l lipofectamine (Life Technologies, San Diego,
CA). Table 2 shows the sequences of the ASODNs and control ODNs,
which were 2-O-methoxy ethyl thioate derivatives (15).
TABLE 2. SEQUENCES OF THE ANTISENSE
OLIGONUCLEOTIDES AND THEIR POSITION
WITHIN THE Bcl-2 mRNA
ASODN No. mRNA Region Base Position Sequence
1011 60 5 UTR 1 CAGCTTTTTATTTCATGAGG
1011 61 39 TGGCATGAGATGCAGGAAAT
1011 62 75 AGTTATGACGAACACTTGAT
1011 63 110 ATGTGCTTTGCATTCTTGGA
1011 64 181 ACTTCGCGTCCCGGCTCCCG
1011 65 205 AAAGAAGCTGCAGGTACCAA
1011 66 Coding R 221 CGCCATCCTTCCGGGGAAAG
1011 67 241 TACCCTGTTCTCCCGGCTTG
1011 68 255 TCTCCCGGTTATCATACCCT
1011 69 265 TTCATCACGATCTCCCGGTT
1011 70 270 TGTACTTCATCACGATCTCC
1011 71 295 CCCCTCTGTGACAGCTTATA
1011 72 301 TCGTAGCCCCTCTGTGACAG
1011 73 321 CTTCATCTCCAGTATCCCAC
1011 74 370 TGGAAGGAGAAGATGCCAGG
1011 75 390 GCGTTCGGTTGCTCTCAGGC
1011 76 421 GTCCTGGCAGCCGTGTCTCG
1011 77 541 AAGTCGCGACGGTAGCGACG
1011 78 671 CCCACCGAACTCAAAGAAGG
1011 79 675 TGACCCCACCGAACTCAAAG
1011 80 781 TTATCCTGGATCCAGGTGTG
1011 81 850 AGCCAGGAGAAATCAAACAG
1011 82 911 GTATGCACCCAGAGTGATGC
1011 83 971 CTTTAGTGAACCTTTTCATA
1011 84 3 UTR 1021 ACAACTTTGTTTCATGGTCC
Definition of abbreviations: ASODN  antisense oligonucleotide; UTR  untrans-
lated region.
Injection of Rats with ASODN and LPS Instillations
Rats were injected intraperitoneally with 0.5 l saline, control ODN,
or ASODNs two times a day at 5 mg/kg in saline for 10 consecutive
days. On Day 7 or 8 of injection, rats were intratracheally instilled with
l mg LPS in 0.5 ml saline or intranasally instilled with 100 l/naris of
1 mg/ml LPS and killed 72 or 48 hours later, respectively.
Histochemical Staining, Quantification, In Situ
Hybridization, Real-Time Polymerase Chain Reaction,
and Western Blot Analysis
Tissue blocks that corresponded to the same nasal anatomic site exam-
ined in the in vitro experiments described previously and intrapulmo-
nary airways of the left lung lobes were obtained as described (16).
Staining and quantification of mucous cell numbers and intraepithelial
stored mucosubstances were performed as described (17–19). Bcl-2 was
detected by immunohistochemistry using two different Bcl-2 antibodies
(BD-Pharmingen, San Diego, CA, or Santa Cruz Biotechnology, Santa
Cruz, CA) at a dilution of 1:1000 or 1:50, respectively, as described
(12). In situ hybridizations, real-time polymerase chain reaction, and
Western blot analyses were performed as described previously (20–22).
See the online supplement for a detailed method description and regard-
ing RNA isolation and polymerase chain reaction.
Statistical Analysis of Data
Data were expressed as the mean group value  SE of the mean.
Differences among groups were examined by analysis of variance and
t tests using SAS software (Cary, NC) and by application of Bonferonni
correction for multiple comparisons. Group means were considered
significantly different when p values were 0.05 or less.
RESULTS
Bcl-2 Expression in Mucous Cells from Subjects with CF
We have previously reported that Bcl-2 is expressed in metaplas-
tic mucous cells of rats exposed to ozone, cigarette smoke (4),
or LPS (5). To further study the relevance of Bcl-2 expression
in human chronic disease, we analyzed lung tissues that were
obtained from individuals with no disease and from individuals
who have CF, pulmonary hypertension, or bronchiectasis. Lungs
from patients with CF were chosen because infections with gram-
negative bacteria are common in these patients and may resemble
the response we see in the rat lung after instillation of LPS (5).
Although an average of 1 to 2% of mucous cells were Bcl-2–positive
in airways from normal subjects or from subjects with other lung
diseases, such as pulmonary hypertension and bronchiectasis, an
average of 8% of mucous cells in lung epithelia of patients with
CF showed immunostaining for Bcl-2 (Figures 1A and 1B). We
noticed heterogeneity in Bcl-2 positivity of mucous cells in some
tissue sections from subjects with CF. In some airways, up to
40% of goblet cells expressed Bcl-2, whereas in adjacent airways,
only 1 to 2% of goblet cells were Bcl-2–positive. The identity
of Bcl-2 was further verified by in situ hybridization, which
showed a strong signal in epithelia where Bcl-2 was detected by
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Figure 1. Increased percentages of mucous cells are Bcl-2–positive in airways of patients
with cystic fibrosis (CF) compared with airways from subjects who have other lung diseases
than CF or control subjects with no disease. Tissue sections were immunostained for Bcl-2
as described in METHODS. Nuclei and intraepithelial mucosubstances stain blue, and Bcl-2
immunostaining was detected with diaminobenzidine and shows brown. (A ) The percent-
age of Bcl-2-positive mucous cells (MCs) was quantified by enumerating the number of
Alcian blue (AB-)–positive MCs and the MCs that had immunostained with the Bcl-2
antibody (BD-Pharmingen). Bar represents 20 m. N  normal; PH  pulmonary hyperten-
sion. (B ) At least 250 AB-positive cells were counted to determine the percentage of positive
Bcl-2 MCs. Values are group means  SEM; n  7 to 10 subjects/group. *Significantly
different from control subjects with no disease, p  0.05. (C ) In situ hybridization of tissue
sections from a subject with CF with antisense (AS) and sense (S) cRNA probes to Bcl-2.
Bar represents 10 m. (D ) Increase in MCs per millimeter of basal lamina (BL) in well
differentiated cultures of primary airway epithelial cells from three subjects without lung
disease and three subjects with CF. *Significantly different from control subjects with no
disease, p  0.05.
immunohistochemistry, whereas the sense control probe showed
no signal (Figure 1C).
To test whether CFTR deficiency is directly responsible for
Bcl-2 expression, primary airway epithelial cells from three subjects
with no lung disease and three subjects with CF were maintained
in culture on an air–liquid interface and allowed to differentiate
into columnar cells. Cells from control subjects and subjects
with CF showed a time-dependent increase in goblet cells per
millimeter of BL over 7, 14, and 21 days (Figure 1D). Significant
differences in goblet mucous cells/millimeter of basal lamina
were observed in the cultures obtained from three normal sub-
jects and three subjects with CF at 7 days, when cells had just
reached confluence. No differences were found at 14 and 21
days, when cells had formed a differentiated columnar epithe-
lium. This finding shows that the change in the number of mucous
cells/millimeter of BL from 7 to 14 days was greater for normal
subjects compared with those with CF. No differences were
observed in the percentage of Bcl-2–positive cells in control and
CF samples (data not shown).
Resolution of LPS-induced GCM in Rats
The number of cells that contain mucosubstances increased from
an average of 15 to an average of 76 cells/mm BL from 2 to 4
days and decreased to approximately 43 cells/mm BL at 8 days
after instillation. The mucous cell numbers decreased to back-
ground levels at 12 days to the numbers found in rats instilled
with saline (8–20 cells/mm BL) throughout the 16 days after
instillation (Figure 2A). The morphology of airway epithelial
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Figure 2. (A ) The number of MCs per millimeter of BL in saline- and
LPS-instilled rats. The number of AB/periodic acid-Schiff (PAS)–positive
epithelial cells were enumerated and normalized to millimeter length
of BL. Values are group means  SEM; n  5 rats/group. *Significantly
different from saline-instilled control animals, p  0.05. (B–G ) Photomi-
crographs of airway epithelia from rats instilled with saline (B–D ) or LPS
(E–G ). Tissue sections were stained with hematoxylin–eosin and AB;
photomicrographs are representative for 2 (B and E ), 3 (C and F ), and
12 (D and G ) days after instillation. Bar represents 20 m.
cells remained cuboidal in saline-instilled rats throughout the
16 days after instillation (Figures 2B–2D). In LPS-instilled rats,
the thickness of the epithelium was already increased at 2 days,
reached maximum ( 21  1.4 m) at 3 to 4 days, and returned
to the original thickness (9.2  0.001 m) at 12 to 16 days after
instillation (Figures 2E–2G).
Accompanying this GCM, a significant increase in Bcl-2–
positive mucous cells (20–30% in LPS rats compared with 3–7%
in saline rats) was found at 2, 3, 4, and 6 days after instillation
in LPS-instilled rats (Figure 3A). No differences between saline-
and LPS-instilled rats were evident 8 to 16 days after instillation.
Although the granular staining of Bcl-2 is visible in Alcian blue–
positive cells at 2 to 6 days, very few cells were immunopositive
at 12 days after instillation (Figures 3B–3D).
Bcl-2 Sustains LPS-induced GCM in Nasal Epithelia
The direct role of Bcl-2 in sustaining metaplastic mucous cells
in airway epithelia was investigated by downregulating its ex-
Figure 3. (A ) Expression of Bcl-2 at various time points after LPS instilla-
tion. The percentage of Bcl-2–positive MCs in rats instilled with saline
or 1000 g LPS from 2 to 16 days after instillation. The tissue sections
were immunostained for Bcl-2 and counterstained with AB to identify
denoting the mucus-producing cells. At least 400 MCs were counted
in each rat to determine the percentage of Bcl-2–positive MCs. Similar
immunostaining was observed with two different antibodies (BD-Phar-
mingen and Santa Cruz) to Bcl-2. *Significantly different from saline-
instilled control animals, p  0.05. (B–D ) Representative photomicro-
graphs show that Bcl-2 is expressed in mucus-producing cells following
LPS instillation. Tissue sections from the left lung at generation 5 from
rats at 2 (B ), 3 (C ), and 12 (D ) days after instillation were immunostained
for Bcl-2 and AB to identify mucus-containing cells. Bcl-2 was detected
with diaminobenzidine and shows brown. Bar represents 20 m.
pression with ASODNs in cultured nasal explants. We screened
25 ASODNs for inhibition of GCM and Bcl-2 mRNA expression
in the organ culture system where GCM can be induced by
treating the distal midseptum from the rat nose with LPS (14).
This screening identified four ASODNs that significantly re-
duced LPS-induced mucous cells in nasal explant cultures (Fig-
ure 4A). Two of four ASODNs (64 and 83) showed a significant
reduction of GCM in repeat experiments and were therefore
selected for testing their efficacy by treating nasal explant cul-
tures at 3-, 30-, 60-, or 90-M concentrations. ASODN 83 effec-
tively reduced GCM, even at 3-M concentrations, whereas
ASODN 64 was most effective at the 90-M concentration (Fig-
ure 4B). In situ hybridization for Bcl-2 mRNA showed a marked
reduction of the mRNA in nasal explants treated with ASODN
64 (Figure 4C). Similar results were observed for ASODN 83
(data not shown).
We further tested whether LPS-induced GCM in distal nasal
midsepta can be reduced by injection of rats with ASODNs to
the Bcl-2 mRNA. Rats were injected intraperitoneally with saline,
control ODN, or ASODN 64 twice per day at 5 mg/kg for 7 days
before LPS instillation and 2 days after instillation. The amount
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Figure 4. (A ) Four of 25 antisense oligonucleotides (ASODNs) significantly
reduced the number of MCs in explant cultures. Organ cultures from rat distal
nasal midsepta were placed in culture on transwell membranes in an air–liquid
interface and treated with 100 g/ml LPS for 24 hours and treated with
30 M ASODNs to Bcl-2 mRNA throughout the 3-day culture period or were left
untreated as control. Explant cultures were fixed 2 days later in zinc formalin,
histochemically stained with AB/PAS to detect acidic and neutral intraepithelial
mucosubstances stored in the epithelial cells, and analyzed for the number of
MCs. The 25 ASODNs were tested in three separate experiments (8–9 ASODNs
with an untreated group as control in each experiment). Error bars represent
group mean values  SEM (n  4 explant cultures/experimental group).
*Significantly different from untreated control explant cultures, p  0.05. (B )
A dose-dependent effect of ASODNs 64 and 83 on stored mucous substances
in the nasal explant cultures. Nasal explants were placed in culture on transwell
membranes, exposed to 100 g LPS for 24 hours, and treated with the respec-
tive ASODNs at 3-, 30-, 60-, or 90-M concentrations throughout the culture
period. Tissues were processed 2 days after LPS treatment, and volume density
(Vs) of stored mucosubstances in the surface epithelium was determined by
morphometry. ASODN 83 shows a significant reduction at 3-M concentra-
tion. ASODN 64 shows a significant reduction only at 90-M concentration.
Bars represent group mean values  SEM (n  4 explant cultures/group).
*Significantly different from untreated controls, p  0.05. (C ) In situ hybridiza-
tion of control ODN- or ASODN 64–treated nasal septa with antisense probe
to Bcl-2 (AS) or with the sense cRNA probe as control (S). Bar represents
15 m. (D ) ASODN 64 reduces the LPS-induced goblet cell metaplasia (GCM)
in the distal nasal septum in in vivo rats. Rats were injected intraperitoneally
with saline control ODN or ASODN 64 mornings and evenings with 5 mg/kg
for a total of 10 mg/kg/day for 9 consecutive days. On Day 7, all rats received
an intranasal instillation (100 l/naris) of a 1-mg LPS solution in saline. Two
days after LPS instillation, rats were killed, and GCM in the epithelium of the
distal nasal septum was quantified by morphometry after histochemical stain
with AB/PAS. Bars represent group mean values  SEM (n  6 rats/experimental
group). *Significantly different from distal septal epithelium of rats injected with
saline or control ODN, p  0.05.
of stored mucosubstances in respiratory epithelia of distal nasal
septa was significantly reduced in rats injected with ASODN 64
compared with those injected with control ODN or saline as
control (Figure 4D).
Bcl-2 Sustains GCM in Pulmonary Airways
The effect of downregulating Bcl-2 expression on LPS-induced
GCM in pulmonary airways was examined by injecting rats intra-
peritoneally with ASODNs 83 and 64 every day for a total of 9
days starting 7 days before intratracheal instillation with 1 mg
LPS. GCM was assessed at 3 days after LPS instillation in the
airway epithelium at generation 5. The total cell number per
millimeter of BL (Figure 5A), the number of mucous cells per
millimeter of BL, and the amount of stored mucosubstances
(Figure 5B) in the airways of rats instilled with LPS were signi-
ficantly reduced by ASODN 64. Furthermore, the percentage
of Bcl-2–positive mucous cells was reduced significantly by
ASODN 64 (Figure 6A). ASODN 83 caused a minor, statistically
nonsignificant reduction of total epithelial cell number and mu-
cous cells per millimeter of BL and of amount in intraepithelial
stored mucosubstances. ASODN 84, which was not effective
in organ culture experiments, showed similar numbers of total
epithelial cells and mucous cells per millimeter of BL and similar
percentages of Bcl-2–positive mucous compared with rats in-
jected with control ODN (data not shown). No differences in
inflammation were observed in lung tissues from control- or
ASODN-treated rats. However, the epithelial thickness was re-
duced when rats were injected with ASODNs 83 and 64, but
not with control ODN (Figure 5D).
The effect of treatment with control ODN or ASODN 83 and
64 on the levels of Bcl-2, Bcl-xL, Bax, and Bak, the major regulators
of this protein family, was tested. The percentage of Bcl-2–positive
mucous cells was more efficiently reduced by ASODN 64 com-
pared with control ODN or ASODN 83 (Figures 6A and 6B).
The protein levels of Bcl-xL, Bax, and Bak were tested in extracts
prepared from the right lungs of three representative rats from
each treatment group. Interestingly, not only Bcl-2 but also
Bcl-xL levels were reduced by treatment with ASODNs 83 and
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Figure 5. ASODN reduces LPS-induced GCM, the Vs, and the number of epithelial cells per millimeter of BL in pulmonary airways in in vivo rats. Rats
were injected intraperitoneally with control (CTL) ODN, ASODN 83, or ASODN 64 twice a day for 10 consecutive days. On Day 7, all rats received
an intratracheal instillation of 1 mg LPS in 500 l. Three days after LPS instillation, rats were killed, and the numbers of MCs per millimeter of BL (A )
and the amount of stored mucosubstances (B ) in the epithelium of airway generation 5 were quantified by morphometry after histochemical stain
with AB/PAS. Adjacent sections were stained with hamatoxylin–eosin followed by AB for quantification of the total numbers of cells per millimeter of
BL (C ). Bars represent group mean values  SEM (n  6 rats/experimental group). *Significantly different than distal septal epithelium of rats injected
with control ODN, p  0.05. (D ) Photomicrographs of axial airways at generation 5 in the left lung lobe of rats injected with control ODN, ASODN
83, and ASODN 64. Tissue sections were stained with hematoxylin–eosin and counterstained with AB. Bar represents 30 m.
64 compared with control ODN (Figure 6C). However, the levels
of the proapoptotic proteins Bax and Bak were not affected by
the ASODN treatments (Figure 6C).
Sustained GCM in Bcl-2 Transgenic Mice
Transgenic mice with Bcl-2 under the control of the MT1 pro-
moter, which is inducible by zinc water, were used to further
Figure 6. Bcl-2 protein levels
are reduced in rats injected with
ASODN 64 compared with con-
trol (CTL) ODN-injected ani-
mals. Bar represents 30 m.
(A, B) The percentage of Bcl-2–
positive MCs was reduced in rats
injected with ASODNs 83 and
64 compared with those in-
jected with control ODN. Bars
represent group mean values 
SEM (n  6 rats/experimental
group). *Significantly different
from control ODN. (C ) Densito-
metric quantification of Bcl-xL,
Bax, and Bak after normalizing
to actin in proteins extracted
from three rat lungs each in-
jected with control ODN and
ASODNs 83 and 64.
establish the role of Bcl-2 expression in sustaining LPS-induced
mucous cell metaplasia. We and others had previously shown
that C56Bl/6 mice instilled with LPS display GCM (13, 23). Bcl-2
expression was 10-fold greater in transgenic compared with wild-
type littermates 8 days after LPS instillation (Figure 7A), and
goblet cells in transgenic but not wild-type mice showed Bcl-2
positivity (Figure 7B). Furthermore, GCM in wild-type mice was
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Figure 7. Sustained Bcl-2 expression in transgenic mice sustains LPS-
induced GCM. Both wild-type (WT) and human Bcl-2 transgenic (TG)
mice with the Bcl-2 transgene under the control of the mouse MT1
promoter on a C57Bl/6 background were maintained on 25 mM zinc
sulfate drinking water to induce transgene expression. Mice were in-
stilled with LPS on 3 consecutive days with 180 g in 50 L saline, a
protocol previously shown to induce maximum GCM in C57Bl/6 mice.
(A ) Increased expression of Bcl-2 was detected 8 days after LPS instilla-
tion in lungs of TG mice that express a zinc-inducible Bcl-2 transgene
in airway epithelia compared with WT mice when they were maintained
on water with zinc sulfate. Bars represent group mean values  SEM
(n  3/group). *Significantly different from WT, p  0.05. (B ) Represen-
tative photomicrographs of Bcl-2 immunostaining cells in WT and TG
(Tg) mice at 8 days after LPS instillation. Bar represents 20 m. (C )
GCM was quantified in these mice over a period of 5 and 8 days after
LPS instillation. GCM was similar in both WT and TG mice at 5 days
after LPS instillation. However, at 8 days, GCM was decreased in WT
but sustained in TG mice.
decreased at 8 days after instillation, but remained elevated in
Bcl-2 transgenic mice (Figure 7C).
DISCUSSION
The present study shows that Bcl-2 is present in airway mucous
cells of subjects with CF and that LPS-induced epithelial prolifer-
ation and GCM is transiently sustained by the expression of this
antiapoptotic protein.
Interestingly, Bcl-2 expression was significantly reduced (as
shown by the percentage of Bcl-2–positive mucous cells and by
Western blot analyses) but not completely suppressed by the
ASODN treatment. This finding suggests that it is not crucial
to completely inhibit Bcl-2 expression to cause the reduction of
epithelial cell numbers and GCM and that proapoptotic signals
initiate the proapoptotic cascade once Bcl-2 and Bcl-xL are re-
duced to a certain threshold level. It is unclear why ASODN 64
was not as effective as ASODN 83 in downregulating GCM in
organ culture but was more effective when injected in rats in-
stilled with LPS. The presence of a large amount of inflammatory
mediators in in vivo rats may result in differences in the stability
of these ASODNs and contribute to this observed difference.
Bcl-2 homology region-3–only subfamily members are known to
induce apoptosis by association with antiapoptotic Bcl-2 family
members or by stimulating other apoptosis-promoting family
members (7, 9, 24, 25).
The reduction of Bcl-2 and Bcl-xL, the major antiapoptotic
proteins, may have allowed the proapoptotic proteins Bax and
Bak to initiate the cell-death process. Although epithelial cells
undergoing cell death are not presented in this study, terminal
deoxy-nucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL-)–positive cells have been detected at the early times
after LPS instillation in mice (26). Furthermore, we have re-
ported that the resolution of allergen-induced GCM is associated
with the presence of TUNEL-positive cells and activated caspase
3 (27). Ongoing studies will characterize the cell death by which
epithelial cells are removed from the epithelium.
The reason why Bcl-xL levels were reduced in lungs when
rats were injected with ASODNs to Bcl-2 is not clear. The homol-
ogy of Bcl-2 and Bcl-xL mRNAs in the regions where ASODNs
83 and 64 are localized is 50%. This level of homology may be
sufficient to bind and downregulate Bcl-xL mRNA because of
similarity in the tertiary structures between these mRNAs. Con-
sistent with our findings, a Bcl-2/Bcl-xL bispecific ASODN inhib-
its the expression of Bcl-2 and Bcl-xL in a representative breast
carcinoma cell line and inhibits the growth and induces death
in cell lines from lung, breast, colorectal, and prostate carcinomas
in vitro (28).
The reduction of Bcl-2 expression with ASODNs decreased
the total epithelial cell number and GCM, thereby directly linking
Bcl-2 expression to GCM. Because the ASODNs were adminis-
tered before LPS instillation, it is possible that the reduction of
Bcl-2 expression affected the inflammation-induced epithelial
cell proliferation. However, our previous studies demonstrate
that approximately half of the Bcl-2–positive cells had undergone
a cell cycle division whereas the other half had not incorporated
BrdU and were therefore derived from preexisting epithelial
cells (2). These studies suggest that Bcl-2 expression is not in-
volved in regulating cell cycle in this system. Further support
for the role of Bcl-2 in sustaining GCM was established by time-
course experiments demonstrating that the reduction of Bcl-2
expression to background levels occurs before the resolution of
GCM (5). In addition, the decrease in Bcl-2–positive mucous
cells seen after injection of rats with bezafibrate was associated
with significant reduction of LPS-induced mucous cells per milli-
meter of BL (12). These observations together with the known
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antiapoptotic function of Bcl-2 (29, 30) confirm that Bcl-2 sus-
tains the lifespan of mucous cells after inflammatory responses.
The reduction of LPS-induced GCM in distal septa as well
as pulmonary airways of rats injected with ASODNs to the Bcl-2
mRNA suggests that the processes involved in the resolution of
GCM in epithelia lining the nasal midsepta and the pulmonary
airways are similar. Our previous studies have established that
Bcl-2 is expressed in ozone- or LPS-induced GCM, both in nasal
and pulmonary airways (4, 5). Because the distal region of the
nasal septum and the main axial pulmonary airways are lined
by a tall columnar respiratory epithelium with primarily serous-
type (not mucous) secretory cells (31, 32), similar regulation of the
resolution process of LPS-induced GCM in these epithelia is not
surprising. These results suggest, therefore, that targeting Bcl-2
expression with ASODN may be useful to reduce GCM and
airway obstruction in humans with bronchopneumonia or rhinitis.
In the rat, the proximal midseptum is lined by a mucociliary
epithelium with endogenous mucous cells. Exposure to ozone
does not change the numbers of mucous cells in this epithelium
but induces GCM in epithelia that line the lateral wall and
the naso- and maxilloturbinates (33). Interestingly, although the
percentage of Bcl-2–positive cells remains low in the proximal
midseptum, up to 50% of mucous cells express Bcl-2 where
metaplastic changes occur (4). Together with our current finding
that Bcl-2 sustains the life span of metaplastic mucous cells, we
conclude that Bcl-2 is expressed only in epithelia where mucous
cell numbers have to be regulated. In addition, the total number
of epithelial cells per millimeter of BL that was reduced in rats
injected with ASODN 64 was similar to the reduction in the
number of mucous cells per millimeter of BL, suggesting that
the epithelium removes primarily mucous cells to restore the
original number of epithelial cells. Therefore, targeting Bcl-2
may primarily reduce metaplastic cells without affecting endoge-
nous mucous cells, which makes this approach valuable and
relevant for therapies in chronic diseases.
The presence of Bcl-2 in mucous cells from subjects with CF
indicates that this protein may be a useful target for reducing
mucous secretions. Our studies with cells from subjects with CF
and control subjects show that cells from subjects with CF are
capable of differentiating to mucous cells, even at the time when
they reach confluence without the formation of a columnar epi-
thelium. The fact that cells from subjects with CF do not have
more mucus-producing epithelial cells compared with control
subjects at confluence indicates a blunted capacity for in vitro
differentiation of CF cells to a mucus-producing phenotype. De-
ficiency in CF is not directly responsible for Bcl-2 expression.
Therefore, it is likely that the presence of bacterial infections
in CF (34) may be causing sustained Bcl-2 expression. It is also
possible that dysregulated expression of Bcl-2 or the presence
of inflammatory mediators sustain activation of Bcl-2 promoter,
causing sustained GCM and airway obstruction. This hypothesis
is supported by our finding that the sustained expression of
Bcl-2 in transgenic mice, where the metallothionein promoter
is activated with zinc water, prolongs the presence of GCM
compared with wild-type mice.
Increased expression of Bcl-2 after inflammatory responses
may be crucial to sustain a transient increase of mucous cell
numbers, for the epithelium to have sufficient mucus to protect
injury by further insults. However, dysregulated expression of
Bcl-2 may sustain GCM to cause disease. Studies have demon-
strated that, in patients with CF and in horses with reactive
airway obstruction, mucous secretions accumulate in airways
and cause obstruction (35, 36). Bcl-2 is also expressed in approxi-
mately 50% of mucous cells in horses with reactive airway ob-
struction (Y.T., personal observation). Thus, our studies showing
Bcl-2 expression in mice, rats, horses, and humans suggest that
resolution of GCM by this mechanism is conserved among spe-
cies and support the hypothesis that targeting Bcl-2 for downreg-
ulation may be useful to reduce mucous cell numbers and allevi-
ate mucous secretions.
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